|
2023 Conference Publication Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case reportEtchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
